Acurx Pharmaceuticals reports full-year 2025 net loss of $8M
Acurx Pharmaceuticals (NASDAQ:ACXP) on Friday reported a full-year 2025 net loss of $8 million, with cash and cash equivalents of $7.6 million as of December 31, 2025, supported by approximately $4 million in gross proceeds from its equity line of credit during the year.










